Medidata and Bioforum Bolster Decade-Long Relationship to Advance Clinical Data and Biometric Solutions for Clinical Trials
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that serves clinical trial sponsors worldwide.
Building on more than a decade of collaboration, the expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more agile clinical development experience. In addition to Medidata solutions such as Medidata Rave EDC and Medidata Rave RTSM, which Bioforum has leveraged to deliver 60 studies across a range of therapeutic areas, the CRO is adding Medidata Clinical Data Studio and Medidata eConsent to streamline data flow, maintain data integrity, and ensure compliance.
“With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for analysis,” said Amir Malka, CEO and co-founder of Bioforum. “We’re excited to be strengthening our alliance with Medidata and, together, providing our customers with the adaptability and advanced solutions they need to thrive.”
“Our expanded partnership with Bioforum brings AI-driven clinical trial management to agile biotech start-ups, accelerating their path to market,” said Janet Butler, executive vice president, head of global sales, Medidata. “By harnessing our Patient Data Surveillance and RBQM platforms, we’re delivering improved operational efficiency for Bioforum and seamless, high-quality data access for their clients.”
Bioforum will sponsor Medidata’s upcoming NEXT New York, a leading clinical trials conference hosted by the company, scheduled for November 13 to 14 in New York City.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
About Bioforum the Data Masters
Bioforum the Data Masters is a leading global clinical research organization (CRO) that specializes in biometric services and solutions for the pharmaceutical, biotech and medical device industries. With a team of experienced professionals and state-of-the-art technology, Bioforum provides a range of services including data management, biostatistics, statistical programming and medical writing to help companies bring new drugs and therapies to market faster. To learn more about us and our services, visit www.bioforumgroup.com or find us on LinkedIn at https://il.linkedin.com/company/bioforum-ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112963841/en/
Contacts
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
Medidata.AR@3ds.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hero MotoSports Team Rally Secures an Impressive 7 th Place Overall Finish at Dakar Rally 202517.1.2025 21:31:00 CET | Press Release
Hero MotoSports Team Rally, the motorsport team of the world’s largest manufacturer of motorcycles and scooters - Hero MotoCorp, has successfully completed the Dakar Rally 2025, reinforcing its position as a formidable force in the world’s toughest rally. The team completed this year’s rally at overall 7th position, registering its second best Dakar performance in nine years, after it finished 2nd overall at the world’s toughest rally last year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250117472643/en/ Hero MotoSports at Dakar Rally Stage 12 (Photo: Business Wire) The team’s young Chilean rider, Nacho Cornejo, delivered a stellar performance, maintaining top-10 standings throughout the rally and securing an overall 7th place finish. Nacho showcased remarkable grit and determination, demonstrating his consistency across the stages. Since Stage 1, he remained in the top-10, climbed to 7th place in Stage 8, and held on to
Qualcomm Announces Quarterly Cash Dividend17.1.2025 15:00:00 CET | Press Release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on March 27, 2025, to stockholders of record at the close of business on March 6, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority
Jefferies Clients, Shareholders and Employees Contribute $10 Million to Charities Supporting Los Angeles Wildfire Relief17.1.2025 14:00:00 CET | Press Release
Jefferies announced today that it will donate $10 million to charities providing aid for first responders and the people and communities impacted by the wildfires across Los Angeles. The donation includes funds from Jefferies, voluntary contributions from its nearly 6,000 worldwide employees, and proceeds from the firm’s January 16 Doing Good Global Trading Day, which set aside 100% of net global trading commissions for charities. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are so grateful for how the Jefferies network stepped up to support those in need in Los Angeles. These wildfires have inflicted heartbreaking devastation on communities and so many families, and we hope this donation will help deserving charities provide urgently needed relief.” Organization Charity Description Allocation Los Angeles Fire Department Foundation The LAFD is actively seeking funds to equip LAFD members battling wildfires with tools and supplies. $2,000,000 All Hands and He
SLB Announces Fourth-Quarter and Full-Year 2024 Results, Increases Dividend and Initiates $2.3 billion in Accelerated Share Repurchases17.1.2025 12:50:00 CET | Press Release
SLB (NYSE: SLB) today announced results for the fourth-quarter and full-year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115789214/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Fourth-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2024Sept. 30, 2024Dec. 31, 2023SequentialYear-on-yearRevenue $9,284 $9,158 $8,990 1% 3% Income before taxes - GAAP basis $1,387 $1,507 $1,433 -8% -3% Income before taxes margin - GAAP basis 14.9% 16.5% 15.9% -151 bps -100 bps Net income attributable to SLB - GAAP basis $1,095 $1,186 $1,113 -8% -2% $0.77 $0.83 $0.77 -7% - Adjusted EBITDA* $2,382 $2,343 $2,277 2% 5% Adjusted EBITDA margin* 25.7% 25.6% 25.3% 8 bps 33 bps Pretax segment operating income* $1,918 $1,902 $1,868 1% 3% Pretax segment operating margin* 20.7% 20.8% 20.8% -11 bps -12 bps Net income attributable to SLB, excluding charges & credits*
Perpetual Atomics and QSA Global Sign Collaboration Agreement17.1.2025 11:03:00 CET | Press Release
Perpetual Atomics is excited to announce this collaboration, which will enable the processing of americium into sealed sources for use in radioisotope power systems, including radioisotope heater units (RHUs) and radioisotope thermoelectric generators (RTGs). This partnership is another step toward supporting sustainable and reliable power solutions for some of the most challenging environments in space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107229344/en/ Perpetual Atomics Team gathered at the University of Leicester (Photo: Business Wire) A University of Leicester spinout, Perpetual Atomics brings over 20 years of expertise in space nuclear power systems and exploration, delivering innovative, reliable solutions for powering space missions in extreme environments, including "surviving the night." QSA Global, with its extensive expertise in designing and producing commercial radioisotope sealed sources for indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom